|
|
|
|
IRVINE--- Edwards Lifesciences Celebrates One Million Heart Valve Patients and More at AATS 2008 |
| 5/8/2008 @ 3:36 PM
print this article -
email to a friend -
join our eNewsletter
|
 |
Edwards Lifesciences Corporation (NYSE:EW) , the world leader in the science of heart valves, announced that the company will celebrate a number of cardiac surgery milestones and product debuts at the 88th annual meeting of the American Association for Thoracic Surgery (AATS), May 10-14 in San Diego.
Among the milestones marked by Edwards -- which this year celebrates its 50th anniversary of partnering with clinicians to develop life-saving innovations -- are:
-- The treatment of more than 1 million patients worldwide with Edwards'
heart valve repair and replacement technologies.
-- The implantation of the Edwards SAPIEN transcatheter aortic heart valve
in more than 1,000 patients worldwide through a series of extensive
clinical trials and feasibility studies in Europe, the U.S. and Canada,
as well as commercial sales in Europe.
-- The start of patient enrollment for transcatheter aortic valve
replacement procedures with the Ascendra transapical delivery system at
participating sites in Edwards' U.S. pivotal trial of the Edwards
SAPIEN valve. Edwards has conditional approval from the U.S. Food and
Drug Administration to perform procedures with both the Ascendra
transapical delivery system and the RetroFlex transfemoral delivery
system at the PARTNER trial sites.
-- Regulatory and reimbursement approval received this week from the
Japanese Ministry of Health for the Carpentier-Edwards PERIMOUNT Magna
pericardial aortic heart valve. As the first and only device of its
kind, this valve combines more than 20 years of clinical experience and
innovation with the most advanced tissue engineering technologies. The
PERIMOUNT Magna valve is the best selling tissue valve in the world.
New Products
Edwards is also introducing and unveiling several new products at AATS:
-- Edwards is offering new arterial and venous cannulae, which are the
flexible tubes used to establish cardiopulmonary bypass in cardiac
surgery. The new cannulae are designed to reduce trauma, increase
efficiency and provide a variety of cannulation site options that
address today's more challenging surgical approach. Among these are the
FemTrak femoral venous cannula and the OptiSite arterial cannula, which
both have proprietary ultra-thin wall technology to help optimize blood
flow while a patient is on a heart-lung machine.
-- The next-generation of the Carpentier-Edwards Physio annuloplasty ring
will be unveiled. This product addresses the degenerative segment of
mitral valve repair -- the largest segment within the repair market --
and features a ring design that better conforms to the patient's
natural anatomy. The original Carpentier-Edwards Physio ring is the
number-one global repair product and was launched in 1994.
"This year Edwards celebrates 50 years of working closely with the surgical community on the development of our pioneering heart valve repair and replacement products and cardiac surgery tools. We look forward to extending this partnership with surgeons as our industry continues to evolve," said Donald E. Bobo, Jr., Edwards' corporate vice president, heart valve therapy. "We will continue this valuable collaboration with surgeons to help shape the emerging minimally-invasive surgery practice and develop transformational therapies for patients. The new Edwards products featured at AATS will also support this goal."
Representatives from Edwards will be in the exhibition area at booth #1001. The booth features information on the new products and simulators for hands-on experience in transcatheter and minimally-invasive surgery techniques.
Clinical Presentations
Among the clinical presentations featuring data about Edwards' devices are:
Sunday, May 11
-- Session V, Percutaneous Aortic Valve Replacement: Update on
Percutaneous AVR with Edwards SAPIEN Valve (retrograde and antegrade)
-- 4:15 p.m. to 4:35 p.m. Ballroom 20 A-C, San Diego Convention
Center. Presenter: John G. Webb, St. Paul's Hospital, Vancouver, BC,
Canada.
-- Session V, Percutaneous Aortic Valve Replacement: Identification of
Appropriate Patients: Who Actually is "Inoperable"? -- 4:55 p.m. to
5:15 p.m. Ballroom 20 A-C, San Diego Convention Center. Presenter:
Michael J. Mack, Cardiothoracic Surgery Associates of North Texas,
Dallas, TX.
Wednesday, May 14
-- Emerging Technologies and Techniques Forum: Is Transcatheter Based
Aortic Valve Implantation Really Less Invasive than Minimal Invasive
Aortic Valve Replacement? -- 7:13 a.m. to 7:26 a.m. Room 25, San Diego
Convention Center. Presenters/authors: Mirko Doss, Sven Martens,
Stephan Fichtelscherer, Thomas Trepels, Gerhard Wimmer Greinecker,
Anton Moritz, Volker Schachinger, Thoracic and Cardiovascular Surgery,
J.W. Goethe University Frankfurt, Frankfurt am Main, Germany.
-- Emerging Technologies and Techniques Forum: Transapical Transcatheter
Aortic Valve Implantation One Year Follow-Up in 19 Patients --
8:05 a.m. to 8:18 a.m. Room 25, San Diego Convention Center.
Presenters/authors: Jian Ye, Anson Cheung, John G. Webb, Daniel R.
Wong, Ronald G. Carere, Christopher R. Thompson, Samuel V.
Lichtenstein, Cardiothoracic Surgery, University of British Columbia,
Vancouver, BC, Canada.
About Edwards Lifesciences
Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Headquartered in Irvine, Calif., Edwards treats advanced cardiovascular disease with its market-leading heart valve therapies, and critical care and vascular technologies. In 2008, Edwards celebrates 50 years of partnering with clinicians to develop life-saving innovations. The company's global brands, which are sold in approximately 100 countries, include CardioVations, Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz. Additional company information can be found at www.edwards.com/. |
| Orange County |
|
|
| |
| Thursday, December 4, 2008 |
 |
|
IRVINE--- ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom 0.09% Posted 3:25 PM PST
MISSION VIEJO--- Steve Geringer Appointed to Aperture Health Board of Directors Posted 9:53 AM PST
NEWPORT BEACH--- White Paper is First of Many TriZetto Resources to Help Payer Organizations Adopt ICD-10 Diagnostic Coding System Posted 7:44 AM PST
IRVINE--- Epicor Cited as an Order Management Solutions Leader by Independent Research Firm Posted 7:43 AM PST
|
| |
| Wednesday, December 3, 2008 |
|
|
IRVINE--- Solarflare Now Shipping Sub 4 Watt, Production-Ready 65nm Triple-Speed 10GBASE-T Silicon Posted 7:27 AM PST
|
| |
| Tuesday, December 2, 2008 |
|
|
ALISO VIEJO--- Networks In Motion Integrates INRIX Total Fusion Traffic into Mobile Navigation Applications Posted 4:14 PM PST
IRVINE--- Mitsubishi Digital Electronics America Announces MH2850U Projector with DICOM Simulation Mode for Medical Training Posted 3:59 PM PST
ALISO VIEJO--- Clarient Introduces Second Gene Mutation Test for Colorectal Cancer Posted 9:00 AM PST
COSTA MESA--- Oxygen Biotherapeutics, Inc. Provides Update on Product Development Plans Posted 8:58 AM PST
LAGUNA NIGUEL--- Aeolus Pharmaceuticals Completes Fifth Closing of Senior Convertible Debt Financing Posted 8:57 AM PST
IRVINE--- Freedom Interactive Launches New Real Estate Vertical Across More than 40 Web Sites Posted 8:56 AM PST
IRVINE--- Visiogen Appoints Seasoned Executive as Chief Financial Officer Posted 8:55 AM PST
IRVINE--- BIOLASE Cuts Back Its Work Force by 20% Posted 8:30 AM PST
IRVINE--- Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors Posted 8:27 AM PST
SAN JUAN CAPISTRANO--- 3DiJoy Launches PC-based Motion-Sensitive Video Gaming Solution in North America Posted 8:26 AM PST
|
| |
| Monday, December 1, 2008 |
|
|
LAGUNA NIGUEL--- Symwave’s Momentum Growing with Key Executive Hires to Lead Company’s Move into High Profile USB 3.0 Market Posted 4:28 PM PST
TUSTIN--- Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies Posted 8:50 AM PST
IRVINE--- Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug Posted 8:44 AM PST
IRVINE--- Westinghouse Licenses AdtekMedia's PumpTop TV Design Posted 8:40 AM PST
IRVINE--- SMC Networks Samples First 320 Mbps Downstream DOSCIS 3.0-based Cable Modem for the Enterprise Posted 8:37 AM PST
IRVINE--- ATEN Technology Launches Combo KVM Switches With PS/2-USB Connectivity Support Posted 8:34 AM PST
IRVINE--- Spectrum Pharmaceuticals Announces ZEVALIN sBLA Granted Priority Review by the FDA; Target Decision (PDUFA) Date of April 2, 2009 American Society of Hematology conference Posted 8:25 AM PST
IRVINE--- Spectrum Pharmaceuticals to Host Conference Call Detailing ZEVALIN Joint Venture and Near-Term Strategy Posted 8:24 AM PST
|
| |
| Monday, November 24, 2008 |
|
|
TUSTIN--- Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals' Bavituximab to Cure Lethal Virus Infections Posted 4:29 PM PST
COSTA MESA--- Irvine Sensors Included in Pilot Program by U.S. Army Posted 4:26 PM PST
ALISO VIEJO--- Valeant Reports Encouraging End of Treatment Results with Taribavirin at Treatment Week 48 in Phase Iib Study Posted 7:48 AM PST
COSTA MESA--- Oxygen Biotherapeutics, Inc. Creates Web-based Shareholder Forum For Interactive Communications With Investors Posted 7:46 AM PST
ALISO VIEJO--- California-Based UST Global is One of 21 Companies Positioned in the 2008 North American Offshore Applications Services Magic Quadrant Posted 7:45 AM PST
|
|
|
|
|
|
FreshNews.com Jobs Change DAILY
We Have 5,000 + Job Listings! Open Your FREE Account
Employers or Job Searchers Get Started Now! Click Here
|
